TITLE

EXIQON REPORTS POSITIVE CLINICAL DATA FROM EORTC TRIAL

PUB. DATE
December 2008
SOURCE
Worldwide Biotech;Dec2008, Vol. 20 Issue 12, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on a multi-institutional prospective randomized clinical trial conducted by the European Organization for Research and Treatment of Cancer (EORTC) on late stage epithelial ovarian cancer patients. Results of the study showed that resistance to carboplatin was a predictor for response to first-line treatment in advanced ovarian cancer patients.
ACCESSION #
35409954

 

Related Articles

  • Ovarian cancer: genomic analysis. Wei, W.; Dizon, D.; Vathipadiekal, V.; Birrer, M. J. // Annals of Oncology;Dec2013 Supplement 10, Vol. 24, px7 

    Objectives Despite improvements in the management of ovarian cancer patients over the last 30 years, there has been only a minimal improvement in overall survival. While targeted therapeutic approaches for the treatment of cancer have evolved, major challenges in ovarian cancer research persist,...

  • Recommended Patient-Reported Core Set of Symptoms and Quality-of-Life Domains to Measure in Ovarian Cancer Treatment Trials. Donovan, Kristine A.; Donovan, Heidi S.; Celia, David; Gaines, Martha E.; Penson, Richard T.; Plaxe, Steven C.; von Gruenigen, Vivian E.; Watkins Bruner, Deborah; Reeve, Bryce B.; Wenzel, Lari // JNCI: Journal of the National Cancer Institute;Jul2014, Vol. 106 Issue 7, p1 

    There is no consensus as to what symptoms or quality-of-life (QOL) domains should be measured as patient-reported outcomes (PROs) in ovarian cancer clinical trials. A panel of experts convened by the National Cancer Institute reviewed studies published between January 2000 and August 2011. The...

  • Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial. Buzzonetti, Alexia; Fossati, Marco; Catzola, Valentina; Scambia, Giovanni; Fattorossi, Andrea; Battaglia, Alessandra // Cancer Immunology, Immunotherapy;Oct2014, Vol. 63 Issue 10, p1037 

    Purpose: To determine whether abagovomab induces protective immune responses in ovarian cancer patients in first clinical remission. The present analysis is a substudy of monoclonal antibody immunotherapy for malignancies of the ovary by subcutaneous abagovomab trial (NCT00418574). Methods: The...

  • Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. Shaw, Heather M.; Hall, Marcia // OncoTargets & Therapy;2013, Vol. 6, p1197 

    Olaparib has shown promising anticancer activity as a single agent in the treatment and maintenance of recurrent ovarian cancer in early clinical trials, but it is far from standard therapy. This article outlines the problem of relapsed ovarian cancer and the mechanisms of poly(ADP-ribose)...

  • Zeltia: opening up options for ovarian cancer.  // PharmaWatch: Biotechnology;May 2005, Vol. 4 Issue 5, p4 

    Reports that a phase III clinical trial to investigate Yondelis for relapsed ovarian cancer has been initiated by Zeltia in the United States. Goal to increase the future commercial potential of the drug; Assessment of efficacy in prolonging survival and to determine which patients are most...

  • Low-Grade Variety Can Be Tougher to Cure.  // USA Today Magazine;Oct2013, Vol. 142 Issue 2821, p5 

    The article discusses the difficulty in treating patients who are suffering from low-grade serous ovarian cancer.

  • Patient-reported outcomes in ovarian cancer clinical trials. Friedlander, M. L.; King, M. T. // Annals of Oncology;Dec2013 Supplement 10, Vol. 24, px64 

    There is general acceptance of the importance of incorporating patient-reported outcome (PRO) measures including health-related quality of life (HRQOL) into clinical trials, and there are now a number of guidance documents available on how to use PRO's for regulatory authorities and in...

  • Olaparib: A Review of Its Use as Maintenance Therapy in Patients with Ovarian Cancer. Frampton, James // BioDrugs;Apr2015, Vol. 29 Issue 2, p143 

    Olaparib (Lynparzaâ„¢) is a first-in-class, orally-active, small molecule, poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in homozygous BRCA-deficient cells. In the EU, the capsule formulation of olaparib is indicated as monotherapy for the maintenance treatment of...

  • Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary†‡. Chuang, E.; Wiener, N.; Christos, P.; Kessler, R.; Cobham, M.; Donovan, D.; Goldberg, G. L.; Caputo, T.; Doyle, A.; Vahdat, L.; Sparano, J. A. // Annals of Oncology;Oct2010, Vol. 21 Issue 10, p2075 

    Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with...

  • BioNumerik Starts Phase III with Improved Chemo Drug. Morisson, Trista // BioWorld Today;2/8/2008, Vol. 19 Issue 27, p1 

    The article reports on the Phase III trial conducted by BioNumerik Pharmaceuticals Inc. comparing Karenitecin with GlaxoSmithKline's Hycamtin, topotecan in relapsed ovarian cancer. The trial will enroll an estimated 500 advanced ovarian cancer patients who have failed first-line treatment with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics